☰

Marc A. Becker, Ph.D. - Publications

Affiliations: 
2010 Pharmacology University of Minnesota, Twin Cities, Minneapolis, MN 
Area:
Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

43 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 DeJong S, Hou X, Zanfagnin V, Evans B, VanBlaricom J, Epler J, Nickles D, Becker M, Oberg A, Heinzen E, Blackwood B, Haluska P, Weroha S. Gemcitabine and novel Chk1 inhibitor GDC-0575 demonstrate synergistic effect against high-grade serous ovarian cancer in 3D cell culture, PDX models and patient tumors Gynecologic Oncology. 159: 90. DOI: 10.1016/j.ygyno.2020.05.072  0.307
2018 Kurokawa C, Iankov ID, Anderson SK, Aderca I, Leontovich AA, Maurer MJ, Oberg AL, Schroeder MA, Giannini C, Greiner SM, Becker MA, Thompson EA, Haluska P, Jentoft ME, Parney IF, et al. Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy. Journal of the National Cancer Institute. PMID 29788332 DOI: 10.1093/Jnci/Djy033  0.303
2017 Butler KA, Hou X, Becker MA, Zanfagnin V, Enderica-Gonzalez S, Visscher D, Kalli KR, Tienchaianada P, Haluska P, Weroha SJ. Prevention of Human Lymphoproliferative Tumor Formation in Ovarian Cancer Patient-Derived Xenografts. Neoplasia (New York, N.Y.). 19: 628-636. PMID 28658648 DOI: 10.1016/J.Neo.2017.04.007  0.398
2017 Zanfagnin V, Bale LK, Becker MA, Hou X, Torres D, Conover CA, Weroha SJ. Abstract 4817: Regression of malignant ascites via PAPP-A inhibition in ovarian cancer patient-derived xenograft model Cancer Research. 77: 4817-4817. DOI: 10.1158/1538-7445.Am2017-4817  0.448
2016 Becker MA, Hou X, Tienchaianada P, Haines BB, Harrington SC, Weroha SJ, Sathyanarayanan S, Haluska P. Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer. Bmc Cancer. 16: 814. PMID 27765027 DOI: 10.1186/S12885-016-2847-3  0.566
2016 AlHilli MM, Becker MA, Weroha SJ, Flatten KS, Hurley RM, Harrell MI, Oberg AL, Maurer MJ, Hawthorne KM, Hou X, Harrington SC, McKinstry S, Meng XW, Wilcoxen KM, Kalli KR, et al. In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma. Gynecologic Oncology. PMID 27614696 DOI: 10.1016/J.Ygyno.2016.08.328  0.318
2016 Martchenko K, Schmidtmann I, Thomaidis T, Thole V, Galle PR, Becker M, Möhler M, Wehler TC, Schimanski CC. Last line therapy with sorafenib in colorectal cancer: A retrospective analysis. World Journal of Gastroenterology. 22: 5400-5. PMID 27340356 DOI: 10.3748/Wjg.V22.I23.5400  0.444
2016 Becker MA, Ibrahim YH, Oh AS, Fagan DH, Byron SA, Sarver AL, Lee AV, Shaw LM, Fan C, Perou CM, Yee D. Insulin Receptor Substrate Adaptor Proteins Mediate Prognostic Gene Expression Profiles in Breast Cancer. Plos One. 11: e0150564. PMID 26991655 DOI: 10.1371/Journal.Pone.0150564  0.717
2016 Long B, Hou X, Becker M, VanBlaricom J, Bradley E, Hendrickson AEW, Oberg AL, Maurer MJ, Heinzen E, Camoriano JK, Colon-Otero G, Burton JK, Kalli K, Foster NR, Haluska P, et al. MC1463: Avatar-directed chemotherapy in platinum-resistant ovarian cancer. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps5609  0.442
2016 Harris FR, Halling GC, Becker MA, Haluska P, Vasmatzis G, Kovtun IV. Abstract 13: Individualized approach for ovarian cancer: Identification of potential therapeutic targets based on genomic analyses, testing efficiency of treatments, and monitoring Clinical Cancer Research. 22: 13-13. DOI: 10.1158/1557-3265.Pmsclingen15-13  0.425
2016 Nitschmann CC, Hurley RM, Becker MA, Hou X, Hoch U, Harding TC, Charych DH, Kaufmann SH, Haluska P, Weroha SJ. Abstract B50: Antineoplastic activity of Top I inhibitor etirinotecan pegol (NKTR-102) and PARP inhibitor rucaparib (CO-388) in platinum-resistant high-grade serous BRCA WT ovarian cancer PDX models. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-B50  0.481
2015 Glaser G, Weroha SJ, Becker MA, Hou X, Enderica-Gonzalez S, Harrington SC, Haluska P. Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft. Plos One. 10: e0126867. PMID 25962155 DOI: 10.1371/Journal.Pone.0126867  0.487
2015 Becker MA, Haluska P, Bale LK, Oxvig C, Conover CA. A novel neutralizing antibody targeting pregnancy-associated plasma protein-a inhibits ovarian cancer growth and ascites accumulation in patient mouse tumorgrafts. Molecular Cancer Therapeutics. 14: 973-81. PMID 25695953 DOI: 10.1158/1535-7163.Mct-14-0880  0.534
2015 Wilcoxen KM, Becker M, Neff C, Abkevich V, Jones JT, Hou X, Wang Y, Hartman A, AlHilli MM, Gutin A, Agarwal S, Timms K, Haluska P. Use of homologous recombination deficiency (HRD) score to enrich for niraparib sensitive high grade ovarian tumors. Journal of Clinical Oncology. 33: 5532-5532. DOI: 10.1200/Jco.2015.33.15_Suppl.5532  0.353
2015 Kumar A, Weroha S, Becker M, Hou X, Greiner S, Karnitz L, Haluska P. Abstract POSTER-THER-1419: Chk1 inhibitor (MK8776) enhances cytotoxicity of gemcitabine in select patient-derived ovarian tumorgraft models Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-Poster-Ther-1419  0.384
2015 Lodhia KA, Becker MA, Hou X, Kalli KR, Harrell MI, Swisher EM, Weroha JS, Haluska P. Abstract 1474: Characterization of 148 ovarian cancer tumografts (Avatars) using BROCA-HR deep sequencing Cancer Research. 75: 1474-1474. DOI: 10.1158/1538-7445.Am2015-1474  0.464
2015 Becker M, Haluska P, Bale L, Oxvig C, Conover C. LBA1A Novel Neutralizing Antibody Targeting PAPP-A Inhibits Tumor Growth and Ascites in Primary Patient Ovarian Tumorgrafts (Ovatars) Annals of Oncology. 26. DOI: 10.1093/Annonc/Mdv098.1  0.504
2015 Lodhia K, Becker M, Hou X, Kalli K, Harrell M, Wilcoxen K, Swisher E, Weroha S, Halsuka P. Characterization of 148 Ovarian Cancer tumografts (Avatars) using BROCA-HR deep sequencing Annals of Oncology. 26: ii31. DOI: 10.1093/Annonc/Mdv096.1  0.414
2015 Kurokawa C, Iankov I, Aderca I, Maurer M, Anderson K, Greiner S, Becker M, Haluska P, Galanis E. 73. Effects of the Innate Immune System on Oncolytic Measles Virotherapy Molecular Therapy. 23. DOI: 10.1016/S1525-0016(16)33678-4  0.389
2015 Mills KA, Becker MA, Febbraro T, Litchfield LM, Lengyel E, Haluska P, Romero I. Advancing metformin as a metabolic therapeutic for ovarian cancer: Testing in non-diabetic patient-derived xenograft avatars Gynecologic Oncology. 137: 63. DOI: 10.1016/J.Ygyno.2015.01.148  0.353
2014 Weroha SJ, Becker MA, Enderica-Gonzalez S, Harrington SC, Oberg AL, Maurer MJ, Perkins SE, AlHilli M, Butler KA, McKinstry S, Fink S, Jenkins RB, Hou X, Kalli KR, Goodman KM, et al. Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1288-97. PMID 24398046 DOI: 10.1158/1078-0432.Ccr-13-2611  0.442
2014 Hou X, Becker MA, Weroha SJ, Butler KA, Greiner SM, Haluksa P. Abstract 1196: Overexpression of IGF-2 in primary patient ovarian cancer tumorgrafts increases bowel and thoracic metastasis Cancer Research. 74: 1196-1196. DOI: 10.1158/1538-7445.Am2014-1196  0.506
2014 Becker M, Hou X, Haluska P. PO3-5: Developing predictive determinants of IGF/INS targeted therapies in ovarian cancer patient tumors and primary tumorgrafts Growth Hormone & Igf Research. 24: S31. DOI: 10.1016/S1096-6374(14)50081-0  0.413
2014 Haluska P, Timms K, AlHilli M, Wang Y, Hartman A, Jones J, Gutin A, Sangale Z, Neff C, Lynchbury J, Rudolph-Owen L, Becker M, Agarwal S, Wilcoxen K. 214 Homologous recombination deficiency (HRD) score and niraparib efficacy in high grade ovarian cancer European Journal of Cancer. 50: 72-73. DOI: 10.1016/S0959-8049(14)70340-5  0.304
2013 Scott CL, Becker MA, Haluska P, Samimi G. Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment. Frontiers in Oncology. 3: 295. PMID 24363999 DOI: 10.3389/Fonc.2013.00295  0.499
2013 Becker MA, Farzan T, Harrington SC, Krempski JW, Weroha SJ, Hou X, Kalli KR, Wong TW, Haluska P. Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth. Molecular Cancer Therapeutics. 12: 2909-16. PMID 24130056 DOI: 10.1158/1535-7163.Mct-13-0547  0.511
2013 Yang Y, Becker MA, Yee D. Abstract 535: IGF-I stimulates amino acid transporter xC- function to reduce intracellular ROS level and promote proliferation in human breast cancer cells. Cancer Research. 73: 535-535. DOI: 10.1158/1538-7445.Am2013-535  0.664
2013 Hilli MA, Weroha SJ, Becker M, Hou X, Harrington S, McKinstrey S, Kalli K, Goodman K, Wilcoxen K, Swisher E, Kaufmann S, Haluska P. Abstract PR05: In vivo antitumor activity of the PARP inhibitor niraparib (MK-4827) in homologous recombination deficient and proficient ovarian cancer Clinical Cancer Research. 19. DOI: 10.1158/1078-0432.Ovca13-Pr05  0.486
2013 Weroha SJ, Haluska P, Becker MA, Harrington SC, Goodman KM, Gonzalez SE, Hilli Ma, Butler KA, Kalli KR, Oberg AL. L11.04Ovarian Avatar Models Predictive Of Platinum Response In Ovarian Cancer Patients Annals of Oncology. 24. DOI: 10.1093/Annonc/Mdt042.51  0.391
2012 Becker MA, Hou X, Harrington SC, Weroha SJ, Gonzalez SE, Jacob KA, Carboni JM, Gottardis MM, Haluska P. IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors Clinical Cancer Research. 18: 1808-1817. PMID 22287600 DOI: 10.1158/1078-0432.Ccr-11-1806  0.547
2012 Gonzalez SE, Weroha SJ, Becker M, Harrington S, Hou X, Haluska P. Abstract 3274: Development of a clinically relevantin vivomodel of ovarian cancer tumorgrafts in immunodeficient mice Cancer Research. 72: 3274-3274. DOI: 10.1158/1538-7445.Am2012-3274  0.448
2012 Becker M, Giri S, Finckenstein F, Lynch M, Gottardis M, Carboni J, Shridhar V, Haluska P. P01-9 BMS-754807 and metformin synergistically inhibit breast and ovarian cancer cell proliferation Growth Hormone & Igf Research. 22: S35-S36. DOI: 10.1016/S1096-6374(12)60090-2  0.389
2012 Hou X, Haines B, Harrington S, Becker M, Weroha J, Sathyanarayanan S, Haluska P. P01-4 Antitumor effect of ridaforolimus (MK-8669) in combination with dalotuzumab (MK-0646) and aromatase inhibitor letrozole in a postmenopausal breast cancer model Growth Hormone & Igf Research. 22. DOI: 10.1016/S1096-6374(12)60085-9  0.452
2012 Butler K, Weroha S, Becker M, Enderica-Gonzalez S, Harrington S, Hou X, Visscher D, Haluska P. Ovarian cancer tumorgraft: Viral latency propagates lymphoma Gynecologic Oncology. 127. DOI: 10.1016/J.Ygyno.2012.07.044  0.422
2011 Becker MA, Ibrahim YH, Cui X, Lee AV, Yee D. The IGF pathway regulates ERα through a S6K1-dependent mechanism in breast cancer cells. Molecular Endocrinology (Baltimore, Md.). 25: 516-28. PMID 21292829 DOI: 10.1210/me.2010-0373  0.647
2011 Rodriguez M, Becker M, Yee D, Potter D. P4-02-11: Insulin-Like Growth Factor I Promotes Estrogen Receptor Positive Breast Cancer Cell Proliferation, in Part, through CYP1A1 Signaling. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P4-02-11  0.526
2011 Becker M, Hou X, Harrington S, Carboni J, Gottardis M, Haluska P. P2-11-11: IGFBP Ratio Confers Resistance to IGF Targeting and Correlates with Increased Invasion and Poor Outcome in Breast Tumors. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P2-11-11  0.549
2011 Yang Y, Becker M, Yee D. P2-03-03: An Insulin-Like Growth Factor I (IGF-I)-Induced Gene, Solute Carrier Family 7 Member 11 (SLC7A11)/xCT, Mediates IGF-I-Induced Biological Behaviors in Breast Cancer Cells. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P2-03-03  0.564
2010 Rodriguez M, Mitra R, Guo Z, Becker MA, Yee D, Potter DA. Abstract 4129: Effects of the metabolism of omega-3 fatty acid EPA by CYP1A1 in breast cancer proliferation and survival Cancer Research. 70: 4129-4129. DOI: 10.1158/1538-7445.Am10-4129  0.619
2009 Yee D, Fagan DH, Zhang X, Oh AS, LaPara K, Becker M, Sachdev D, Zhang H. Abstract CN07-02: Disrupting insulin‐like growth factor signaling with monoclonal antibodies Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-Cn07-02  0.741
2009 Becker M, Yee D. IGF-I mediated phosphorylation of ERαS167 occurs downstream of mTOR/p70S6K1 to impact nuclear localization and chromatin interaction. Cancer Research. 69: 6012. DOI: 10.1158/0008-5472.Sabcs-6012  0.47
2009 Becker M, Ibrahim Y, Byron S, Sarver A, Silverstein K, Lee A, Yee D. IGF-Induced Gene Profiles Are Dependent on IRS Expression and Convey Prognostic Value in Human Breast Cancer. Cancer Research. 69: 3031-3031. DOI: 10.1158/0008-5472.Sabcs-09-3031  0.726
2009 Yee D, Zhang X, LaPara K, Fagan D, Ibrahim Y, Zhang H, Zeng X, Becker M, Sachdev D. 58 Inhibition of IGF signalling as cancer therapy European Journal of Cancer Supplements. 7: 17. DOI: 10.1016/S1359-6349(09)70061-8  0.672
Show low-probability matches.